• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Alerts
CMECNE

Gonorrhea: New CDC Diagnosis and Treatment Guidelines

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Utilize the appropriate diagnostic test for gonorrhea
2. Select the appropriate ‘dual’ antibiotic approach when treating gonorrhea

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Dec 31 2017 through Dec 31 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Read Disclaimer & Fine Print

There has been a major change in the treatment of GC (12/2020). The CDC no longer recommends dual therapy. The current guideline, summarized below, specifies a single agent approach.

CLINICAL ACTIONS:

Annual screening for gonococcal infection (GC) (N. gonorrhoeae) is recommended for all sexually active women aged <25 years and for older women at increased risk for infection (e.g., those who have a new sex partner, more than one sex partner, a sex partner with concurrent partners, or a sex partner who has a sexually transmitted infection).

To diagnosis GC :

  • Perform nucleic acid amplification testing (NAAT), which detects genetic material of N. gonorrhoeae
    • More sensitive than culture
    • Faster results than culture
    • Easy to obtain from a vaginal swab
    • Currently approved for genital (vaginal, endocervical) and urine samples
    • Can NOT determine antibiotic resistance

          OR

  • Culture for N. gonorrhoeae
    • Requires endocervical swab, not vaginal
    • Available for rectal, oropharyngeal, and conjunctival gonococcal infection

NOTE: Obtain BOTH NAAT and culture in the case of treatment failure to determine bacterial susceptibility to antibiotics

SYNOPSIS:

Specific microbiologic diagnosis of infection with N. gonorrhoeae should be performed in all persons at risk for, or suspected to have, gonorrhea. A specific diagnosis can potentially reduce complications, reinfections, and transmission. The CDC no longer recommends combination therapy for uncomplicated GC

KEY POINTS:

For Uncomplicated Gonococcal Infections of the Cervix, Urethra and Rectum

  • <150 kg (300 lb): Ceftriaxone 500 mg IM as a single dose
  •  ≥150 kg (300 lb): 1 g of IM ceftriaxone
  • If chlamydial infection has not been excluded
    • Treat for chlamydia with doxycycline 100 mg orally twice daily for 7 days
    • During pregnancy, azithromycin 1 g as a single dose is recommended to treat chlamydia

If Ceftriaxone is Unavailable

  • Gentamicin 240 mg IM as a single dose plus azithromycin 2 g orally as a single dose or
  • Cefixime 800 mg orally as a single dose | If treating with cefixime, and chlamydial infection has not been excluded, providers should treat for chlamydia with doxycycline 100 mg orally twice daily for 7 days | During pregnancy, azithromycin 1 g as a single dose is recommended to treat chlamydia

Uncomplicated Gonococcal Infections of the Pharynx

  • <150 kg (300 lb): Ceftriaxone 500 mg IM as a single dose
  •  ≥150 kg (300 lb): 1 g of IM ceftriaxone
  • If chlamydial infection has not been excluded
    • Treat for chlamydia with doxycycline 100 mg orally twice daily for 7 days
    • During pregnancy, azithromycin 1 g as a single dose is recommended to treat chlamydia

Note: No reliable alternative treatments are available for pharyngeal gonorrhea

Additional Notes

  • Instruct patient to abstain from sexual activity for 7 days after treatment and until all sex partners are adequately treated (7 days after receiving treatment and resolution of symptoms, if present)
  • Test for other STIs, including chlamydia, syphilis and HIV
  • A test-of-cure is not needed for persons who receive a diagnosis of uncomplicated urogenital or rectal gonorrhea who are treated with any of the recommended or alternative regimens
  • In the case of pharyngeal gonorrhea treated with an alternative regimen, the patient should return 14 days after treatment for a test-of cure using either culture or NAAT
    • If NAAT positive, do a confirmatory culture and antimicrobial susceptibility testing
  • Retest after 3 months
    • Recurrence may not be treatment failure but rather reinfection
    • In States where legally allowed (see learn more below), consider Expedited Partner Therapy (EPT) which allows the patient herself to provide medications to her partner when there are limited public health services to treat a partner, or concern that the partner will not have access to treatment
  • Treat women with HIV with the same recommended regimen
  • Consult infectious disease specialist in case of allergies to cephalosporin

Diagnosis codes:

  • Gonorrhea–nonpregnant A54.00 (PID A54.24, vaginal gonorrhea A54.02 other sites have other codes)
  • Gonorrhea in pregnancy: 098.21X (1st trimester 098.211, 2nd trimester 098.212,
  • 3rd trimester 098.213)
  • Complicating childbirth 098.22
  • In the puerperium: 098.23

Learn More – Primary Sources:

CDC: Gonococcal Infections in Adolescents and Adults

AACC: Chlamydia and Gonorrhea NAAT Screening Method Endorsed by CDC

CDC Gonorrhea Fact Sheet for your patients

Update to CDC’s Treatment Guidelines for Gonococcal Infection, 2020

Take a post-test and get CME credits

TAKE THE POST TEST

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite

< Previous
All Alerts Posts
Next >

Related ObG Topics:

Gonorrhea Treatment Pearls
Sexually Transmitted Diseases and Partner Notification
Chlamydia: CDC Recommendations for Diagnosis and Treatment
Pelvic Inflammatory Disease – CDC Treatment Guidelines
Practical obstetrics info for your women's healthcare practice
STD Screening in Pregnancy: CDC Recommendations
Screening & Treatment of Gynecologic infections in the HIV-Positive Woman
Screening for Sexually Transmitted Diseases – Who, When and How Often?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site